592177
Sacituzumab Biosimilar, Human Trop-2
Size
£607.00
- SKU:
- 592177
- Purity:
- ≥95% (reducing SDS-PAGE, HPLC). Endotoxin: ≤1EU/mg (LAL)
- Storage Conditions:
- -20°C
- Supplier:
- United States Biological
- Host:
- Human
- Immunogen:
- Recombinant Sacituzumab biosimilar produced in mammalian cells.
- Format:
- Supplied as a 0.2uM filtered solution, pH 6.2. No stabilizers or preservatives added.
- Extra Details:
- Sacituzumab Biosimilar uses the same protein sequences as the therapeutic antibody sacituzumab. Sacituzumab govitecan is a Trop-2-directed antibody and topoisomerase inhibitor drug conjugate used for the treatment of metastatic triple-negative breast cancer and metastatic urothelial cancer. Triple-negative breast cancer is a type of breast cancer that tests negative for estrogen receptors, progesterone receptors and human epidermal growth factor receptor 2 (HER2) protein. Therefore, triple-negative breast cancer does not respond to hormonal therapy medicines or medicines that target HER2. Sacituzumab govitecan is a conjugate of the humanized anti-Trop-2 monoclonal antibody linked with SN-38, the active metabolite of irinotecan. Each antibody having on average 7.6 molecules of SN-38 attached. SN-38 is too toxic to administer directly to patients, but linkage to an antibody allows the drug to specifically target cells containing Trop-2. Applications: Suitable for use in ELISA, Neutralization, Functional Assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by Sacituzumab. Other applications not tested. Recommended Dilution: Optimal dilutions to be determined by the researcher. Storage and Stability: May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for 12 months after receipt. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
- Shipping Conditions:
- Blue Ice